TORL BioTherapeutics Strengthens Leadership with CEO Appointment of Aran Maree

TORL BioTherapeutics LLC (TORL), a clinical stage oncology focused biotechnology company, announced a leadership transition to position the Company for its next phase of growth. Effective as of May 1, 2026, Aran Maree, M.D., is appointed Chief Executive Officer (CEO) and Board Member. Dr. Maree succeeds Mark Alles, who will continue to support the Company as Chairman of the Board.

"TORL was founded to discover, develop, and commercialize first- and best-in-class cancer therapeutics. Given Aran's highly successful, multi-decade industry career, and the leadership he has demonstrated throughout his tenure as TORL's first Chief Medical Officer, the Board and I are confident he has the experience, insight, and passion to continue to guide TORL through and beyond this critical next phase of clinical milestones," said Mark J. Alles, Chairman of TORL BioTherapeutics. "His appointment reflects a carefully planned leadership transition designed to position TORL for growth and operational scale, and I look forward to continuing to work with Aran and the rest of the TORL team to improve patient outcomes."